Passionate about Progress
We are a clinical-stage biopharmaceutical company that is developing the investigational therapy Haduvio™ (oral nalbuphine ER) to help patients suffering with chronic cough by targeting the central and peripheral cough reflex arc.
We released positive results from our Phase 2b CORAL trial for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and our Phase 2a RIVER trial for the treatment of refractory chronic cough (RCC). We look forward to continuing development for these patients.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT and we are proud to be part of its vibrant life-science community.
“At Trevi Therapeutics, we are dedicated to the development of Haduvio for patients with chronic cough in Idiopathic Pulmonary Fibrosis and Refractory Chronic Cough. Our team is committed to improving patients’ lives. Each day, we work with the purpose of making a meaningful impact, focused on delivering a therapy for those affected by chronic cough.”
– Jennifer Good, Co-Founder, President & CEO